WO2014119969A1 - 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법 - Google Patents
보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법 Download PDFInfo
- Publication number
- WO2014119969A1 WO2014119969A1 PCT/KR2014/000920 KR2014000920W WO2014119969A1 WO 2014119969 A1 WO2014119969 A1 WO 2014119969A1 KR 2014000920 W KR2014000920 W KR 2014000920W WO 2014119969 A1 WO2014119969 A1 WO 2014119969A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antibody
- binding fragment
- antigen
- protein
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention relates to antibodies against C5, and to the prophylaxis and treatment of complement-related disorders using such antibodies.
- the complement system is the first step in innate immunity, which not only plays a role in recognizing and destroying infectious agents most quickly, but also plays an important role in linking innate and acquired immunity through interactions with immune cells. Doing.
- the complement system is activated through three pathways, the classical pathway, the alternative pathway, and the lectin pathway, followed by the various types of complement proteins.
- Complement proteins effectively eliminate external infectious agents such as activating the secretion of inflammatory substances, interacting with immune cells to regulate the inflammatory response, and creating substances that can attack infectious agents.
- Complementary system is complementary and complement regulatory protein because it prevents excessive increase in complement activity by various kinds of complement regulatory proteins, maintains homeostasis and plays a key role in various stages of inflammatory and immune responses. If not properly controlled it is known to cause a variety of diseases.
- C5 is a single sequence of 1676 amino acids consisting of a signal sequence of 18 residues and an Arg-rich linker sequence (RPRR) located between the mature N-terminal beta chain ( ⁇ -chain) and the C-terminal alpha chain ( ⁇ -chain). It is expressed intracellularly as a pro-C5 peptide.
- Mature C5 has a molecular weight of about 190 kDa and consists of two polypeptide chains ( ⁇ , 115 kDa and ⁇ , 75 kDa) linked by disulfide bonds.
- the C5 convertase cleaves C5 between residues 74 and 75 of the alpha chain to release a 74 amino acid C5a peptide, and then a C5b fragment to be incorporated into the membrane attack complex (MAC).
- MAC membrane attack complex
- Anaphylatoxin C5a directly activates leukocytes and platelets and acts as a chemotactic factor of neutrophils.
- C5b forms a membrane attack complex with C6, C7, C8, and C9 in the final stage of complement activity to induce cell hemolysis.
- autoimmune diseases and complement related diseases When the complement system is overactivated, abnormal immune responses occur and normal cell damage occurs, so the abnormal activity of the complement system is associated with autoimmune diseases and complement related diseases. Hemocytic hemolysis is a complement-related disease caused by genetic defects in which blood cells are not protected from the attack of complement proteins. Intense immune and tissue destruction reactions in rheumatoid arthritis and transplantation are also associated with complement activity. In addition to the immune response due to complement activity, elution of substances such as VEGF occurs due to tissue damage, and neovascularization is formed. It has been reported to lead to degeneration and diabetic retinopathy.
- composition comprising a complement inhibitor, a method of treating or preventing a complement-related disease, and a use thereof.
- the present invention relates to complement C5-binding molecules (eg, C5-binding antibodies or antigen-binding fragments thereof), pharmaceutical compositions comprising such molecules, methods of making such molecules and compositions, methods of using these molecules and compositions, and such It provides the use of molecules and compositions.
- complement C5-binding molecules eg, C5-binding antibodies or antigen-binding fragments thereof
- pharmaceutical compositions comprising such molecules, methods of making such molecules and compositions, methods of using these molecules and compositions, and such It provides the use of molecules and compositions.
- the present invention provides an antibody or antigen-binding fragment thereof that specifically binds a C5 protein.
- the invention also includes a heavy chain variable region having at least 90%, 95%, 97%, 98% or at least 99% sequence identity to any one selected from SEQ ID NOs: 7, 17, 27, 37, 47 or 57 Nucleic acid comprising a nucleotide sequence encoding a polypeptide is provided.
- the invention also provides for a nucleotide encoding a polypeptide comprising a light chain variable region having at least 90%, 95%, 97%, 98% or at least 99% sequence identity to SEQ ID NOs: 8, 18, 28, 38, 48 or 58
- nucleic acids comprising sequences.
- the present invention also provides a vector and a host cell comprising the nucleic acid.
- the present invention also provides pharmaceutical compositions comprising one or more C5-binding molecules of the invention (eg, C5 binding antibodies or antigen binding fragments thereof).
- C5-binding molecules of the invention eg, C5 binding antibodies or antigen binding fragments thereof.
- the present invention also provides a method of treating or diagnosing a complement related disease using a C5 binding molecule.
- the present invention also provides a C5 binding molecule; And it provides a kit for diagnosing complement-related diseases comprising a container.
- the present invention also provides the use of a C5 binding molecule for the manufacture of a medicament for the treatment of complement related diseases.
- the present invention also provides the use of C5 binding molecules for the treatment of complement related diseases.
- the present invention provides an antibody or antigen-binding fragment thereof that specifically binds a C5 protein.
- the antibody or antigen-binding fragment thereof of the present invention inhibits complement activation through specific binding to the C5 protein, thereby preventing or treating complement-related diseases.
- an “antibody” of the invention includes an intact antibody and any antigen binding portion or single chain thereof.
- Naturally occurring “antibodies” are glycoproteins comprising at least two heavy chains (H) and two light chains (L), interconnected by disulfide bonds.
- Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH).
- the heavy chain constant region consists of three domains of CH1, CH2 and CH3.
- Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL).
- the light chain constant region consists of one domain CL.
- the VH and VL regions can be further subdivided into hypervariable regions called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FR).
- CDRs complementarity determining regions
- Each VH and VL consists of three CDRs and four FRs, which are arranged in the following order from amino terminus to carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- the variable regions of the heavy and light chains contain binding domains that interact with the antigen.
- the antibody or antigen-binding fragment thereof that specifically binds to the C5 protein of the invention specifically binds to the beta chain ( ⁇ -chain) of C5, more specifically to the MG4 domain of the C5-beta chain. More specifically, based on the amino acid sequence of the beta chain, the sequence of amino acid residues 332 to 398, preferably 332 to 378, more preferably 332 to 364, even more preferably 332 to 348 and / or 350 to 420, preferably 369-409, more preferably 379-398, even more preferably 386-392.
- a bindable C5 protein wherein the amino acid sequence of human C5 protein is SEQ ID NO: 61, the amino acid sequence of the beta chain of human C5 protein is SEQ ID NO: 62 and the amino acid sequence of the MG4 domain of the beta chain of human C5 protein is SEQ ID NO: It is presented at 63.
- Other species also have cross-reactivity between species such as rabbits, rats, and monkeys.
- the antibody or antigen-binding fragment thereof that specifically binds to a C5 protein of the invention comprises at least 1 ⁇ 10 7 M ⁇ 1 , 1 ⁇ 10 8 M ⁇ 1 , 1 ⁇ 10 9 M ⁇ 1 , 1 ⁇ Has an affinity constant (K A ) of 10 10 M ⁇ 1 , or 1 ⁇ 10 11 M ⁇ 1 .
- the antibody or antigen-binding fragment thereof of the present invention is an antibody or antigen-binding fragment thereof that binds the same epitope as the antibodies described in Tables 1-6, and at least 90%, 95%, 97%, Antibodies with 98% or at least 99% sequence identity and complement inhibitory activity are also within the scope of the present invention.
- some modifications apparent in the constant regions of the heavy and light chains are included in the scope of the present invention in the range having the same pseudo complement inhibitory activity.
- each of these antibodies can bind C5
- the VH, VL, full length light chain and full length heavy chain sequences are “mixed and matched” to other C5 of the present invention.
- -Binding antibodies can be generated.
- the antibody may include an antibody comprising amino acids homologous to the antibodies described in Tables 1 to 6, including the above-mentioned antibodies; Having a heavy chain variable region comprising CDR1, CDR2 and CDR3 sequences, and a light chain variable region comprising CDR1, CDR2 and CDR3 sequences, wherein at least one of these CDR sequences is based on an antibody described herein or a conservative modification thereof
- An antibody having a specific amino acid sequence and retaining the functional properties of the C5-binding antibody of the invention An antibody that binds to the same epitope as the antibodies described in Tables 1-6; All of the antibodies prepared using antibodies having one or more VH and / or VL sequences set forth herein as starting materials for engineering the modified antibody, and which have some altered properties from the starting antibody.
- the antibody includes a modification of framework residues in VH and / or VL to improve the properties of the antibody.
- the antibody may be a fully human antibody that specifically binds to the C 5 protein. It may have more reduced antigenicity when administered to human subjects as compared to chimeric antibodies and the like.
- Human antibodies include heavy or light chain variable regions or full-length heavy or light chains that are products of or derived from specific germline sequences when the variable region or full-length chain of the antibody is obtained from a system using human germline immunoglobulin genes. Such systems include immunizing transgenic mice carrying a human immunoglobulin gene with an antigen of interest, or screening using a library of human immunoglobulin genes displayed on phage.
- Human antibodies derived from or derived from human germline immunoglobulin sequences are identified by comparing the amino acid sequence of a human antibody to the amino acid sequence of a human germline immunoglobulin and selecting a human germline immunoglobulin sequence that is closest to the sequence of the human antibody. Can be.
- the antibody may be a bispecific or multispecific antibody.
- the antibody or antigen-binding fragment thereof of the invention may be a bispecific molecule that binds to two or more different binding sites or target molecules.
- an antibody of the invention is a monoclonal antibody that specifically binds a C5 protein.
- an antibody of the invention can be a human or humanized monoclonal antibody or chimeric antibody that specifically binds a C5 protein, and the antibody of the invention comprises a human heavy chain constant region and a human light chain constant region.
- the antibody of the present invention may be a single chain antibody, the antibody of the present invention may be a Fab fragment, may be a single-chain variable fragment (scFv), may be IgG isotype.
- Preferred IgG isotypes are IgG2, IgG4 and / or IgG2 / 4.
- the IgG isotype of the invention is IgG2 / 4.
- the IgG2 / 4 hybrid constant region may be a fusion of the CH1 and hinge regions of IgG2 and the CH2 and CH3 regions of IgG4.
- Monoclonal antibodies can be produced by conventional monoclonal antibody methods, and the synthesized antibody genes can be expressed and purified by inserting into an antibody expression vector, preferably pcDNA, pCI, pCMV, pCEP4 and the like.
- viral or carcinogenic transformation of B lymphocytes can be used and can be prepared based on the sequence of murine monoclonal antibodies prepared using the murine system.
- standard molecular biology techniques can be used to obtain DNAs encoding heavy and light chain immunoglobulins from murine hybridomas and to contain non-murine immunoglobulin sequences.
- human monoclonal antibodies against C5 can be prepared using transgenic or transchromosomal mice bearing portions of the human immune system that are not the mouse immune system.
- the invention provides an antibody or antigen-binding fragment thereof comprising a framework in which an amino acid is substituted with an antibody framework from each human VH or VL germline sequence.
- an antibody or antigen-binding fragment thereof that specifically binds to a C5 protein of the invention is SEQ ID NO: 1, 2, 3, 4, 5, 6, 11, 12, 21, 22, 31, 32, 41, At least one complementarity determining (CDR) sequence having at least 95% sequence identity to 42, 51 or 52.
- CDR complementarity determining
- an antibody or antigen-binding fragment thereof that specifically binds to a C5 protein of the invention may comprise SEQ ID NO: 1, 2, 3, 11, 12, 21, 22, 31, 32, 41, 42, 51 or 52; One or more heavy chain complementarity determining sequences that are identical.
- an antibody or antigen binding fragment thereof that specifically binds a C5 protein of the invention comprises one or more light chain complementarity determining sequences identical to SEQ ID NO: 4, 5 or 6.
- the antibody or antigen-binding fragment thereof that specifically binds to a C5 protein of the invention comprises any one heavy chain CDR1, SEQ ID NO: 2, 12 selected from SEQ ID NO: 1, 11, 21, 31, 41 or 51 , Heavy chain CDR2 selected from 22, 32, 42 or 52, and / or any heavy chain CDR3 selected from SEQ ID NO: 3, 13, 23, 33, 43 or 53.
- the antibody or antigen-binding fragment thereof that specifically binds to the C5 protein of the invention comprises light chain CDR1 of SEQ ID NO: 4, light chain CDR2 of SEQ ID NO: 5, and / or CDR3 of SEQ ID NO: 6.
- the antibody or antigen-binding fragment thereof that specifically binds to a C5 protein of the invention comprises any of the heavy chain variable regions selected from SEQ ID NOs: 7, 17, 27, 37, 47 or 57, or A heavy chain variable region having at least 90%, 95%, 97% or at least 99% sequence identity to any of the heavy chain variable regions selected from Nos. 7, 17, 27, 37, 47 or 57.
- the antibody or antigen-binding fragment thereof that specifically binds a C5 protein of the present invention comprises a light chain variable region of SEQ ID NO: 8, or at least 90%, 95%, 97 in a light chain variable region of SEQ ID NO: 8 Light chain variable regions having% or at least 99% sequence identity.
- the antibody or antigen-binding fragment thereof that specifically binds a C5 protein of the invention comprises any heavy chain selected from SEQ ID NO: 9, 19, 29, 39, 49 or 59, or SEQ ID NO: 9, A heavy chain variable region having at least 90%, 95%, 97% or at least 99% sequence identity to any heavy chain selected from 19, 29, 39, 49 or 59.
- the antibody or antigen-binding fragment thereof that specifically binds to a C5 protein of the invention comprises a light chain of SEQ ID NO: 10, or at least 90%, 95%, 97% or at least 99 to the light chain of SEQ ID NO: 10 Light chains with% sequence identity.
- the antibody or antigen-binding fragment thereof that specifically binds to the C5 protein of the invention comprises binding to an epitope in the beta chain of the C5 protein of SEQ ID NO: 62.
- the invention also includes a heavy chain variable region having at least 90%, 95%, 97%, 98% or at least 99% sequence identity to any one selected from SEQ ID NOs: 7, 17, 27, 37, 47 or 57 Nucleic acid comprising a nucleotide sequence encoding a polypeptide is provided.
- a nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a heavy chain variable region of the invention comprises the sequence of Table 7 below, or at least 90%, 95%, 97%, 98% or Have at least 99% sequence identity.
- nucleic acids comprising a nucleotide sequence encoding a polypeptide comprising a light chain variable region having at least 90%, 95%, 97%, 98% or at least 99% sequence identity in SEQ ID NO: 8.
- a nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a light chain variable region of the invention comprises the sequence of Table 8 below, or at least 90%, 95%, 97%, 98% or at least 99% Has sequence identity of
- the present invention also provides a vector and a host cell comprising the nucleic acid.
- the invention provides a host cell comprising (1) a recombinant DNA fragment encoding a heavy chain of an antibody of the invention, and (2) a second recombinant DNA fragment encoding a light chain of an antibody of the invention.
- the invention provides host cells comprising recombinant DNA fragments encoding each of the heavy and light chains of an antibody of the invention.
- the antibody or antigen binding fragment thereof is a human monoclonal antibody or antigen binding fragment thereof.
- Various expression vectors can be used to express polynucleotides encoding C5-binding antibodies, chains or binding fragments, and both viral-based and non-viral expression vectors can be used to generate antibodies in mammalian host cells.
- Vectors such as pcDNA, pCI, pCMV, pCEP4 and host cells such as HEK293, CHO and CHO-DG44 can be used.
- Host cells bearing and expressing C5-binding antibodies can be prokaryotic or eukaryotic.
- E. Coli preferably E. coli ER2738. HB2151, BL21 and the like, and are prokaryotic hosts useful for cloning and expressing polynucleotides of the invention.
- Other microbial hosts suitable for use include Bacillus, for example Bacillus subtilis, and other enteric bacteria, for example Salmonella, Serratia and various Pseudomonas species.
- Other microorganisms such as yeast can be used to express the C5-binding polypeptides of the invention, and insect cells in combination with baculovirus vectors can also be used.
- mammalian host cells are used to express and prepare C5-binding polypeptides of the invention.
- it may be a hybridoma cell line expressing an endogenous immunoglobulin gene or a mammalian cell line carrying an exogenous expression vector.
- any animal or human cell can secrete numerous immunoglobulins, including, for example, CHO cell lines, Cos cell lines, HeLa cells, myeloma cell lines, HEK cell lines, transformed B-cells and hybridomas.
- Suitable host cell lines can be used, preferably HEK293, CHO, CHO-DG44.
- the present invention also provides pharmaceutical compositions comprising one or more C5-binding molecules of the invention (eg, C5 binding antibodies or antigen binding fragments thereof).
- C5-binding molecules of the invention eg, C5 binding antibodies or antigen binding fragments thereof.
- Complement-related diseases include all diseases and pathological conditions in which the development of the disease is associated with abnormalities in the activation of the complement system, eg, complement deficiency.
- Inflammatory and autoimmune diseases such as rheumatoid arthritis (RA), degenerative arthritis, acute respiratory distress syndrome (ARDS), remote tissue damage after ischemia and reperfusion, complement activation during cardiopulmonary bypass, dermatitis, pemphigus, lupus erythematosus Nephritis, glomerulonephritis, glomerulonephritis, cardiopulmonary bypass, heart attack-induced coronary endothelial dysfunction, type II mesenchymal glomerulonephritis, acute renal failure, antiphospholipid syndrome, macular degeneration, endophthalmitis, neovascular disease, allogeneic Transplantation, acute rejection, hemodialysis, chronic obstructive pulmonary respiratory distress syndrome (COPD), asthma, nocturnal hemoglobuloglobuloglobuloglobulo
- composition may further contain one or more other agents suitable for treating or preventing complement related diseases.
- Pharmaceutical carriers enhance or stabilize the composition or facilitate the preparation of the composition.
- Pharmaceutically acceptable carriers include physiologically compatible solvents, dispersion media, coatings, anti-bacterial and anti-fungal agents, isotonic and absorption delaying agents, and the like.
- the pharmaceutical composition of the present invention can be administered by various methods known in the art.
- the route and / or mode of administration depends on the desired result. It is preferred that the administration is intravenous, intramuscular, intraperitoneal or subcutaneous or in close proximity to the target site.
- antibodies of the invention are formulated for intravitreal administration into the eye.
- the active compounds ie antibodies, bispecific and multispecific molecules, may be coated with materials that protect the compound from the action of acids and other natural conditions that may inactivate the compound.
- the composition must be sterile and fluid. Proper fluidity can be maintained, for example, by the use of coatings such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. In many cases, it is desirable to include isotonic agents, for example, sugars, polyalcohols such as mannitol or sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be induced by including in the composition an agent that delays absorption, such as aluminum monostearate or gelatin.
- compositions of the present invention can be prepared according to methods known in the art and commonly practiced. See, eg, Remington: The Science and Practice of Pharmacy, Mack Publishing Co., 20th ed., 2000 and Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.
- the pharmaceutical composition is preferably prepared under GMP conditions.
- therapeutically effective or potent doses of C5-binding antibodies are used in the pharmaceutical compositions of the present invention.
- C5-binding antibodies are formulated in pharmaceutically acceptable dosage forms by conventional methods known to those skilled in the art. Dosage regimens are adjusted to provide the optimum desired response (eg, a therapeutic response).
- the actual dosage level of the active ingredient in the pharmaceutical composition of the present invention may be varied such that an amount of active ingredient that is effective for achieving the desired therapeutic response for a particular patient, composition, and mode of administration, is not toxic to the patient.
- the dosage level chosen is dependent on the various pharmacodynamic factors, e.g., the activity of the particular composition of the invention used, or esters, salts or amides thereof, the route of administration, the time of administration, the rate of release of the specific compound used, the duration of treatment, the specific Other drugs, compounds and / or substances used in combination with the composition, the age, sex, weight, condition, general health and previous medical history and other factors of the patient being treated.
- the dosage range is from about 0.0001 to 100 mg, more generally 0.01 to 15 mg per kg body weight of the host.
- Exemplary therapies involve systemic administration once every two weeks, or once per month, or once every three to six months.
- the dosage ranges from about 0.0001 to about 10 mg.
- Exemplary therapies involve systemic administration once every two weeks, or once per month, or once every three to six months.
- the dosage is adjusted to achieve a plasma antibody concentration of 1 to 1000 ⁇ g / mL, and in some methods 25 to 500 ⁇ g / mL.
- the antibody can be administered as a sustained release formulation when less frequent administration is desired. Dosage and frequency vary depending on the half-life of the antibody in the patient. In prophylactic use, relatively low doses are administered at relatively rare intervals over a long period of time.
- the present invention also provides a method of treating or diagnosing complement related diseases using a C5 binding molecule.
- Methods of treating complement related diseases using C5 binding molecules of the invention include administration of a therapeutically effective amount of an antibody or antigen binding fragment thereof or a composition comprising the same.
- therapeutically effective amount refers to an amount of a C5 binding molecule of the invention or a composition comprising the same that is effective for the prevention or treatment of complement related diseases.
- agents suitable for combination therapy with C5-binding antibodies include agents known in the art that can modulate the activity of the complement component. For example, phosphonate esters, polyanionic materials, sulfonyl fluorides, polynucleotides, fimaric acid, various anti-inflammatory agents, and the like. Combination therapy with one or more therapeutic agents and the like may be additive and may result in synergy.
- the present invention includes diagnostic assays that determine C5 protein and / or nucleic acid expression and C5 protein function in biological samples (eg, blood, serum, cells, tissues) or from individuals suffering from or at risk of developing a complement related disease. do.
- Antibodies of the invention can be used for the detection of complement cleavage products, for example, radioimmunoassays, ELISAs and radial diffusion assays.
- diagnostic assays, prognostic assays, pharmacogenetics, and clinical trial monitoring can be used to prophylactically treat a subject by prognostic (predictive) purposes, and the present invention also relates to a disorder in which the subject is associated with dysregulation of complement pathway activity.
- Prognostic (or predictive) tests are provided to determine whether the disorder is at risk of developing. For example, mutations in the C5 gene can be assayed in biological samples. By using such assays for prognostic or predictive purposes, one can prophylactically treat an individual prior to the onset of a disorder characterized or related to C5 protein, nucleic acid expression or activity.
- the present invention also provides a C5 binding molecule; And it provides a kit for diagnosing complement-related diseases comprising a container.
- the diagnostic kit of the present invention may comprise any one or more of the above-mentioned C5 binding molecules.
- the container includes a solid carrier, and the C5 binding molecule can be attached to the solid carrier, which solid carrier can be porous or nonporous, planar or nonplanar.
- the present invention also provides the use of a C5 binding molecule for the manufacture of a medicament for the treatment of complement related diseases.
- the C5 binding molecule of the present invention for the manufacture of a medicament or a composition comprising the same may be mixed with an acceptable carrier and the like, and may be prepared in a complex formulation with other agents to have a synergistic action of the active ingredients.
- the present invention also provides the use of C5 binding molecules.
- C5 binding molecules for the treatment of complement related diseases of the present invention can be used for therapeutic purposes and are used to diagnose C5 protein and / or nucleic acid expression and also C5 protein function from an individual suffering from or at risk of developing a complement related disease. It can be used for.
- C5 binding molecules of the invention are useful for the diagnosis, prevention and treatment of complement-related diseases.
- 1 is a diagram showing the absorbance of 40 clones randomly selected after bio-panning using immune libraries of rabbits (A) and chickens (B) according to an embodiment of the present invention.
- Figure 2 is a view showing the absorbance measurement results for human C5 of the five antibodies selected from the rabbit and chicken immune library and the control antibody Ekulizumab according to an embodiment of the present invention.
- Figure 3 is a diagram showing the results obtained by securing a large number of clones having binding capacity to C5 from five variant sub-library.
- Figure 4 is a view showing the result of comparing the binding capacity of the improved affinity clone prepared using the humanized clone HRA-06 clone according to an embodiment of the present invention as a template.
- FIG. 5 is a diagram showing that the antibody prepared according to an embodiment of the present invention has a high complement-dependent cytotoxicity inhibitory activity in the complement-dependent cytotoxicity assay.
- FIG. 6 is a diagram showing the high C5a production inhibitory ability of the antibody prepared according to an embodiment of the present invention.
- Figure 7 is a diagram showing the cross-sectional cross-reactivity of the monoclonal antibody prepared according to an embodiment of the present invention.
- FIG. 8 is a diagram showing the results of size exclusion chromatography of antibodies prepared and purified according to an embodiment of the present invention.
- FIG. 9 is a diagram showing that the antibody binds to the beta chain of C5 according to an embodiment of the present invention.
- FIG. 10 is a diagram showing that the antibody binds to the MG4 domain of the beta chain of C5 according to an embodiment of the present invention.
- FIG. 11 is a diagram showing that the antibody specifically binds to the MG4 domain in the variant Fc fusion protein sequentially removed one domain from the C-terminus of the beta chain according to an embodiment of the present invention.
- FIG. 12 is a diagram showing that the antibody binds to the N-terminal 332-348th amino acid residue of the beta chain as confirmed by immunoblot in a sequential deletion variant of the MG4 domain.
- Figure 13 is a diagram showing that the antibody binds to the amino acid residues of the 379-398th beta-chain N-terminal as confirmed by the ELISA according to an embodiment of the present invention.
- FIG. 14 is a diagram showing that the antibody binds to the beta chain N-terminal 386-392 (MG4 domain sequence basis: 55-61 th amino acid sequence) th amino acid residue according to one embodiment of the present invention as confirmed by ELISA.
- Single-chain Fv libraries were prepared using the primers of Table 9 (rabbit) and Table 10 (chicken) specific for the heavy and light chain variable regions of immunoglobulins.
- the 10 (9 ⁇ V ⁇ and 1 ⁇ V ⁇ ) a combination of one or a combination of on was used for the encoding sequence amplification, for the chicken V ⁇ and V H of about scFv libraries VH of four primers and V L rabbit was used.
- cDNA was mixed with 60 pmol of each primer, 10 ⁇ l of 10 X reaction buffer, 8 ⁇ l of 2.5 mM dNTP, 0.5 ⁇ l of Taq DNA polymerase and water to a final volume of 100 ul. It was. PCR reactions were carried out under the following conditions: 30 cycles 15 seconds 94 ° C., 30 seconds 56 ° C., and 90 seconds 72 ° C., followed by a final extension of 10 minutes 72 ° C. Amplified sections of about 350 bp were purified with QIAEX II Gel Extraction Kit (QIAGEN, Valencia, CA, USA) after loading and running on 1.5% agarose gel.
- QIAEX II Gel Extraction Kit QIAGEN, Valencia, CA, USA
- each PCR reaction contained 100 ng of purified V L and V H product, 60 pmol of each primer, 10 ⁇ l of 10 ⁇ reaction buffer, 8 ⁇ l of 2.5 mM dNTP and 0.5 ⁇ l of Taq DNA polymerase. performed with a mixture of ul. PCR reactions were carried out under the following conditions: 20 cycles 15 seconds 94 ° C., 30 seconds 56 ° C., and 2 minutes 72 ° C., followed by a final extension of 10 minutes 72 ° C. An about 700 bp scFV fragment was purified with QIAEX II Gel Extraction Kit (QIAGEN).
- scFv fragments and pComb3XSS vectors were cleaved at 50 ° C. for 8 hours by Sfi I restriction enzymes (Roche Molecular Systems, Pleasanton, CA, USA). 700 ng of Sfi I-cleaved scFv was ligated with 1400 ng of pComb3X vector using T4 DNA ligase by incubation of the reaction at 16 ° C. for 12 hours, followed by ethanol precipitation. The ligated library was transformed by electoporation with E. coli ER2738. The cells were mixed in 3 ml Super Broth (SB) medium at 37 ° C.
- SB Super Broth
- Input and output phage titers were determined by plating phage infected bacteria on LB plates containing 50 ug / ml carbenicillin and incubating at 37 ° C. The next day phage was precipitated by addition of PEG-8000 and NaCl as in Example 1.
- ELISA was performed using phage diplaying scFv on human C5 to analyze clones selected from biopanning.
- 96-well plates were coated overnight at 4 ° C. with 100 ng of human C5 and blocked with PBS containing 3% BSA.
- Each phage culture was mixed with the same amount of 6% BSA containing PBS and then added to human C5-coated 96-well plates and incubated at 37 ° C. for 2 hours. After incubation and washing was performed, the cells were incubated with HRP-bound anti-M13 antibody (Amersham, USA).
- a of FIG. 1 represents an immune library of rabbits
- B of FIG. 1 represents an immune library of chickens.
- ELISA of anti-C5 scFv-Fc fusion protein against C5 was performed on five selected scFv clones to compare the binding ability with the control antibody, eculizumab.
- the amount of antibody bound to C5 was determined using HRP-bound anti-human IgG, and the results are shown in FIG. 2.
- CDRs Six antigen complementarity determining regions (CDRs) that make up the scFv antibody segment having binding and activation inhibitory activity against human complement C5 (light chain antigen complementarity determining regions [CDRL 1-3], heavy chain antigen complementarity determining regions 1-). 3 [CDRH1-3] portion was inserted between the eight frameworks of human germline kappa1 / IGHV3-23 / (FRL1-4, FRH1-4) to synthesize humanized anti-complement C5 scFv gene (HRA- 06, Genscript, Piscataway, NJ, USA).
- the HRA-06 scFv gene was used as template DNA. Random codons were introduced into the five CDRs except for CDRH3 by PCR. Amplified scFv fragments were purified by QIAEX II Gel Extraction Kit (QIAGEN). ScFV and pComb3XSS vectors were cleaved with SfiI restriction enzyme (Roche Molecular Systems) and ethanol precipitated after ligation. The ligated library was transfected into E.
- Example 3 coli ER2738 as in Example 1 and a phage library was prepared. Antigens were selected in the same manner as in Example 2 based on the prepared phage library. Finally, binding to C5 was confirmed by phage ELISA in the same manner as in Example 3.
- eculizumab synthesized heavy and light chain genes based on the antibody sequences specified in the examination report of eculizumab (product name Soliris), which is registered with the Japanese Medical Device Management Agency (PMDA).
- Transfection was performed on overexpressed recombinant protein.
- 2 ug of mammalian expression vector and 4 ug of polyethylenimine / ml (PEI, Polysciences, Warrington, PA, USA) per ml of culture volume were mixed in 150 mM sodium chloride, equivalent to 1/10 of the culture volume. It was left for a minute.
- HEK 293F cells (2 ⁇ 10 6 cells / ml) were added to the mixture and FreeStyle TM 293 expression culture containing 100 U / ml penicillin (Invitrogen) and 100 U / ml streptomycin (Invitrogen) for 5 days, 37 ° C., 7% CO 2 And incubated under agitation conditions of 135 rpm.
- Supernatants of cell exclusion were collected and subjected to Protein A affinity gel chromatography for purification of IgG and Fc fusion proteins.
- An enzyme-linked immunosorbent assay was performed to measure complement C5 binding ability of the antibody produced by the method of Example 5. The reaction was carried out by diluting and adding the antibody to a 96-well plate coated with C5. Absorbance was measured in the same manner as in Example 3 by using a horseradish peroxidase-labeled anti-human IgG antibody as a secondary antibody and coloring with ABTS (2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid] -diammonium salt) It was.
- ABTS 2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid] -diammonium salt
- the types of monoclonal antibodies used in the experiment were six affinity matured humanized anti-C5 antibodies (HRA-06-H2-1, HRA-06-H2-7, HRA-06-H2-18, HRA-06-H2-). 24, HRA-06-H1-9-H2-7, HRA-06-H1-9-H2-24) and the positive control antibody Eculizumab, the negative control antibody Palivizumab, and the experimental results are shown in FIG. .
- RaJi a CD-20 expressing human Burkitt's lymphoma cell line
- RPMI 1640 10% FBS (Invitrogen), 100 U / ml penicillin (Invitrogen) and 100 U / ml streptomycin (Invitrogen).
- Target cells were mixed at a concentration of 1 ⁇ 10 6 cells / ml after washing.
- Rituximab an anti-CD20 human IgG
- CDC solution at a concentration of 3 ug / ml.
- Equal volumes of target cells and sensitive antibodies were mixed to make a volume of 100 ul / well in 96-well plates and left for 5 minutes at room temperature.
- the assay was started by adding human complement serum, with a final volume of 150 ul per well and final concentration of 4% serum. After 2 hours incubation, 15 ul Tetrazolium salt (WST-1, Takara Bio, Japan) was added and the plate was incubated for 2 more hours. Living cells were measured at 450 nm OD. The effect of anti-C5 antibodies was assessed by serum and pretreatment at 37 ° C. for 30 minutes prior to addition of the target cell and sensitive antibody mixtures. Palibizumab at the same concentration was used as an IgG control. The percentage of cell viability was calculated by the following formula.
- the affinity matured humanized anti-C5 antibody prepared according to the present invention exhibited CDC inhibitory activity, and all of the antibodies showed high cell viability compared to eculizumab.
- Immunoblot was performed to confirm that the monoclonal antibody binds to complement C5 of other species. Dilutions of human C5 protein and serum of human (Sigma), rhesus monkey, BALB / c mice, Wistar rats, and NZW rabbits were SDS-PAGE, respectively, and the separated proteins were transferred to nitrocellulose membranes. Immunoblot was performed using the anti-complement C5 antibody HRA-06-H2-1 prepared according to the present invention.
- anti-complement C5 antibody showed binding to C5 of human (Sigma), rhesus monkey, Wistar rat, NZW rabbit.
- Purified antibodies were subjected to size-exclusion chromatography (SEC) analysis using a Waters 2489 system (Waters Corporation, Milford, MA, USA) and a Zenix-C 300 column (Sepax Technologies, Inc., Newark, DE, USA). .
- the mobile phase composition 150 mM sodium phosphate, pH 7.0
- flow rate 1.0 mL / min
- concentration of protein was determined by monitoring the absorbance of the column eluate at 280 nm.
- the concentration of fractions was calculated by dividing each peak area by the sum of the peak areas.
- FIG. 8A to 8D respectively show A) HRA-06-H2-1, B) HRA-06-H2-7, C) HRA-06-H2-18, D) HRA-06-H2-24, E) HRA-06-H1-9-H2-7 and F) HRA-06-H1-9-H2-24.
- FIG. 9A confirms the binding using eculizumab as an antibody
- FIG. 9B shows the result of using HRA-06-H2-1 according to the present invention as an antibody.
- eculizumab binds to C5 (complementary protein) and binds to alpha chains in 2 lanes of Reducing.
- the HRA-06-H2-1 antibody according to the present invention was bound to C5 (complete complement protein), it was confirmed that the binding to beta chain in 2 lanes that performed Reducing.
- Sequential deletion variants of the beta chain and the six domains that make up the beta chain of C5 were amplified from cDNA. Primers were designed to be added to the SfiI restriction sites at the 5 'and 3' ends (Table 11). Sequential elimination variants of the beta chains were amplified by primer combinations as described in Table 12. The amplified PCR fragments were cleaved with SfiI and cloned into pCEP4 vectors modified to contain the hinge site and the CH2-CH3 domain of human IgG1 at the 3 ′ portion of the cloning site. These clones were transfected as described in Example 5 above and the Fc fusion protein was purified.
- FIG. 10A shows a schematic diagram of the structure of the C5 beta chain and the prepared Fc fusion protein
- FIG. 10B shows the immunoblot result.
- the HRA-06-H2-1 antibody prepared according to the present invention binds to an Fc fusion protein having a MG4 domain.
- FIG. 11A shows a schematic diagram of the structure of the C5 beta chain and the prepared Fc fusion protein
- FIG. 11B shows the immunoblot result.
- the HRA-06-H2-1 antibody binds only to the Fc fusion protein containing the MG4 domain.
- FIG. 12A shows the MG4 domain and the Fc fusion protein prepared by sequential removal
- FIG. 12B shows the results of immunoblot with HRA-06-H2-1 antibody.
- FIG. 12 it was confirmed that no binding was performed to the variants in which the 332-348th sequence was removed from the N-terminus of the beta chain, and thus, the 332-348th amino acid residue in the MG4 domain of the beta chain. It was found that the sequence was a sequence with high antibody binding potential.
- Human / mouse hybrid MG4 domain of C5 beta chain was prepared by overlap extension PCR. Primers were designed to add SfiI restriction sites at both the 5 'and 3' ends (Table 14). PCR fragments were cleaved with SfiI and cloned into SfiI cleaved pComb3X vector. These clones were transfected with E. coli ER 2738. Single colonies from each human / mouse MG4 hybrid were incubated at 600 nm until absorbance reached 1.0. Phage infection was performed by the addition of VCSM13 helper phage (10 11 pfu / ml) and incubated at 37 ° C. for 2 hours. Kanamycin (25 ug / ml) was added and the incubation was overnight at 37 ° C. with constant stirring. The bacteria were removed by centrifugation at 3000 g for 15 minutes.
- Phage ELISA was performed as follows. HRA-06-H2-7, anti-C5 IgG2 / 4, was diluted in 0.1 M sodium bicarbonate buffer (pH 8.6) and 100 ng of the antibody was coated in 96-well plates overnight at 4 ° C. Each well was blocked by the addition of 5% skim milk in TBS containing 0.05% of 100 ul Tween 20 and incubated at 37 ° C. for 1 hour. Phage were diluted 2-fold in 6% BSA / PBS and diluted 50 ul phages were added to each well and incubated at 37 ° C. for 2 hours.
- Plates were washed, 50 ul of diluted HRP-bound anti-M13 antibody (1: 5000) was added and incubated at 37 ° C. for 1 hour. After washing the plate a 50 ul ABTS substrate solution was added to each well and the absorbance was measured at 405 nm.
- FIG. 13A shows the human / mouse hybrid MG4 domain
- FIG. 13B shows the ELISA results.
- the HRA-06-H2-7 antibody bound when the amino acid residue sequence of 379-398 based on the beta chain sequence was a human sequence, showing the possibility of binding to that portion of the antibody. .
- FIG. 14 is a result of confirming the sequence binding site in more detail.
- FIG. 14A shows the human / mouse hybrid MG4 domain
- FIG. 14B shows the ELISA results.
- HRA-06-H2-7 antibody binds when the amino acid residue sequence of 386-392 (based on MG4 domain sequence: 55-61th amino acid sequence) based on the beta chain sequence is a human sequence This shows the possibility of binding to that part of the antibody.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
Abstract
Description
Claims (37)
- 보체 C5 단백질 베타쇄의 MG 4 도메인에 특이적으로 결합하는 항체 또는 이의 항원 결합 단편.
- 제1항에 있어서, 상기 보체 C5 단백질 베타쇄의 에피토프는 보체 C5 단백질 베타쇄의 332 내지 348번째 아미노산 잔기 서열 및/또는 386 내지 392번째 아미노산 잔기 서열을 포함하는, 항체 또는 이의 항원 결합 단편.
- 제1항에 있어서, 상기 보체 C5 단백질 베타쇄의 에피토프는 보체 C5 단백질 베타쇄의 332 내지 398번째 아미노산 잔기 서열 및/또는 350 내지 420번째 아미노산 잔기 서열에 포함되는, 항체 또는 이의 항원 결합 단편.
- 제1항에 있어서, 표 1 내지 6에 기재된 항체 중 어느 하나와 동일한 에피토프를 가지는, 항체 또는 이의 항원 결합 단편.
- 제1항에 있어서, 항체는 단일클론 항체인, 항체 또는 이의 항원 결합 단편.
- 제1항에 있어서, 항체는 인간 또는 인간화 항체인, 항체 또는 이의 항원 결합 단편.
- 제1항에 있어서, 항체는 IgG 이소형인, 항체 또는 이의 항원 결합 단편.
- 제1항에 있어서, 항체는 IgG2의 힌지(hinge)와 IgG4의 Fc의 융합단백질을 포함하는, 항체 또는 이의 항원 결합 단편.
- 서열번호 1, 2, 3, 4, 5, 6, 11, 12, 21, 22, 31, 32, 41, 42, 51 또는 52에 95% 이상의 서열 동일성을 가지는 1개 이상의 상보성 결정 (CDR) 서열을 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 서열번호 1, 2, 3, 11, 12, 21, 22, 31, 32, 41, 42, 51 또는 52와 동일한 1개 이상의 중쇄 상보성 결정 서열을 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 서열번호 4, 5 또는 6과 동일한 1개 이상의 경쇄 상보성 결정 서열을 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 서열번호 1, 11, 21, 31, 41 및 51로 이루어진 군으로부터 선택된 중쇄 CDR1, 서열번호 2, 12, 22, 32, 42 및 52로 이루어진 군으로부터 선택된 중쇄 CDR2, 및 서열번호 3의 중쇄 CDR3을 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 제12항에 있어서, 서열번호 4, 5 및 6으로부터 선택되는 경쇄 CDR을 추가로 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 제13항에 있어서, 서열번호 1의 중쇄 CDR1, 서열번호 2의 중쇄 CDR2, 서열번호 3의 중쇄 CDR3, 서열번호 4의 경쇄 CDR1, 서열번호 5의 경쇄 CDR2 및 서열번호 6의 경쇄 CDR3을 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 제13항에 있어서, 서열번호 11의 중쇄 CDR1, 서열번호 12의 중쇄 CDR2, 서열번호 3의 중쇄 CDR3, 서열번호 4의 경쇄 CDR1, 서열번호 5의 경쇄 CDR2 및 서열번호 6의 경쇄 CDR3을 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 제13항에 있어서, 서열번호 21의 중쇄 CDR1, 서열번호 22의 중쇄 CDR2, 서열번호 3의 중쇄 CDR3, 서열번호 4의 경쇄 CDR1, 서열번호 5의 경쇄 CDR2 및 서열번호 6의 경쇄 CDR3을 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 제13항에 있어서, 서열번호 31의 중쇄 CDR1, 서열번호 32의 중쇄 CDR2, 서열번호 3의 중쇄 CDR3, 서열번호 4의 경쇄 CDR1, 서열번호 5의 경쇄 CDR2 및 서열번호 6의 경쇄 CDR3을 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 제13항에 있어서, 서열번호 41의 중쇄 CDR1, 서열번호 42의 중쇄 CDR2, 서열번호 3의 중쇄 CDR3, 서열번호 4의 경쇄 CDR1, 서열번호 5의 경쇄 CDR2 및 서열번호 6의 경쇄 CDR3을 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 제13항에 있어서, 서열번호 51의 중쇄 CDR1, 서열번호 52의 중쇄 CDR2, 서열번호 3의 중쇄 CDR3, 서열번호 4의 경쇄 CDR1, 서열번호 5의 경쇄 CDR2 및 서열번호 6의 경쇄 CDR3을 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 서열번호 7, 17, 27, 37, 47 또는 57에 95% 이상의 서열 동일성을 갖는 중쇄 가변 영역을 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 서열번호 8에 95% 이상의 서열 동일성을 갖는 경쇄 가변 영역을 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 서열번호 9, 19, 29, 39, 49 또는 59에 95% 이상의 서열 동일성을 갖는 중쇄를 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 서열번호 10에 95% 이상의 서열 동일성을 갖는 경쇄를 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 제20항에 있어서, 서열번호 8에 95% 이상의 서열 동일성을 갖는 경쇄 가변 영역을 추가로 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 제22항에 있어서, 서열번호 10에 95% 이상의 서열 동일성을 갖는 경쇄를 추가로 포함하는, 인간 C5 단백질에 결합하는 단일클론 항체 또는 이의 항원 결합 단편.
- 제1항 내지 제25항 중 어느 한 항에 따른 단일클론 항체 또는 이의 항원 결합 단편을 포함하는 약학적 조성물.
- 서열번호 7, 17, 27, 37, 47 또는 57에 95% 이상의 서열 동일성을 갖는 중쇄 가변 영역을 포함하는 폴리펩티드를 코딩하는 뉴클레오티드 서열을 포함하는 핵산.
- 서열번호 8에 95% 이상의 서열 동일성을 갖는 경쇄 가변 영역을 포함하는 폴리펩티드를 코딩하는 뉴클레오티드 서열을 포함하는 핵산.
- 제27항 및/또는 제28항의 핵산을 포함하는 벡터.
- 제29항의 벡터를 포함하는 숙주세포.
- 보체 관련 질환의 치료가 필요한 대상체에게 제1항 내지 제25항 중 어느 한 항의 항체 또는 이의 항원 결합 단편의 치료학적으로 유효한 양을 투여하는 것을 포함하는, 보체 관련 질환의 치료 방법.
- 제31항에 있어서, 상기 대상체는 인간인, 보체 관련 질환의 치료 방법.
- 제32항에 있어서, 보체 관련 질환은 류마티스성 관절염(RA), 퇴행성 관절염, 급성 호흡 곤란 증후군 (ARDS), 허혈 및 재관류 이후의 원거리 조직 손상, 심폐 우회술 동안 보체 활성화, 피부근염, 천포창, 낭창성 신염, 사구체신염, 사구체혈관염, 심폐 바이패스, 심장마비-유도된 관상동맥 내피 기능 이상, 제II형 막증식성 사구체신염, 급성 신부전증, 항인지질 증후군, 황반 변성증, 안내염, 신혈관 질환, 동종이식, 초급성 거부반응, 혈액투석, 만성 폐쇄성 폐 호흡곤란 증후군 (COPD), 천식, 야간 혈색소뇨증(PNH) 및 흡인성 폐렴으로부터 선택되는, 보체 관련 질환의 치료 방법.
- 제1항 내지 제25항 중 어느 한 항의 항체 또는 이의 항원 결합 단편; 및 용기를 포함하는 보체 관련 질환의 진단용 키트.
- 제1항 내지 제25항 중 어느 한 항의 항체 또는 이의 항원 결합 단편을 이용한 보체 관련 질환의 예측 및 진단 방법.
- 제1항 내지 제25항 중 어느 한 항의 항체 또는 이의 항원 결합 단편을 이용한 보체 관련 질환 치료 용도.
- 보체 관련 질환 치료용 약제의 제조를 위한 제1항 내지 제25항 중 어느 한 항의 항체 또는 이의 항원 결합 단편의 용도.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112015018438A BR112015018438A2 (pt) | 2013-01-31 | 2014-02-03 | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento |
CN201480019466.4A CN105143261B (zh) | 2013-01-31 | 2014-02-03 | C5抗体以及用于预防和治疗补体-相关的疾病的方法 |
EP14746443.2A EP2975055A4 (en) | 2013-01-31 | 2014-02-03 | C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES |
US14/764,885 US10280215B2 (en) | 2013-01-31 | 2014-02-03 | Anti-C5 antibodies and methods of treating complement-related diseases |
JP2015555921A JP6608702B2 (ja) | 2013-01-31 | 2014-02-03 | 補体関連疾患の予防及び治療のためのc5抗体及び方法 |
AU2014213147A AU2014213147B2 (en) | 2013-01-31 | 2014-02-03 | C5 antibody and method for preventing and treating complement-related diseases |
CA2899589A CA2899589C (en) | 2013-01-31 | 2014-02-03 | C5 antibody and method for preventing and treating complement-related diseases |
RU2015136078A RU2663349C2 (ru) | 2013-01-31 | 2014-02-03 | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний |
AU2019202606A AU2019202606B2 (en) | 2013-01-31 | 2019-04-15 | C5 antibody and method for preventing and treating complement-related diseases |
US16/388,550 US11339210B2 (en) | 2013-01-31 | 2019-04-18 | Anti-C5 antibodies and methods of treating complement-related diseases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361759015P | 2013-01-31 | 2013-01-31 | |
US61/759,015 | 2013-01-31 | ||
US201361862248P | 2013-08-05 | 2013-08-05 | |
US61/862,248 | 2013-08-05 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/764,885 A-371-Of-International US10280215B2 (en) | 2013-01-31 | 2014-02-03 | Anti-C5 antibodies and methods of treating complement-related diseases |
US16/388,550 Continuation US11339210B2 (en) | 2013-01-31 | 2019-04-18 | Anti-C5 antibodies and methods of treating complement-related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014119969A1 true WO2014119969A1 (ko) | 2014-08-07 |
Family
ID=51262613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/000920 WO2014119969A1 (ko) | 2013-01-31 | 2014-02-03 | 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법 |
Country Status (10)
Country | Link |
---|---|
US (2) | US10280215B2 (ko) |
EP (1) | EP2975055A4 (ko) |
JP (2) | JP6608702B2 (ko) |
KR (1) | KR101638931B1 (ko) |
CN (1) | CN105143261B (ko) |
AU (2) | AU2014213147B2 (ko) |
BR (1) | BR112015018438A2 (ko) |
CA (1) | CA2899589C (ko) |
RU (2) | RU2663349C2 (ko) |
WO (1) | WO2014119969A1 (ko) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9765135B2 (en) | 2014-12-19 | 2017-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies |
JP6202774B1 (ja) * | 2016-06-17 | 2017-09-27 | 中外製薬株式会社 | 抗c5抗体および使用方法 |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US10633434B2 (en) | 2016-06-14 | 2020-04-28 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibodies |
EP3390442A4 (en) * | 2015-12-18 | 2021-01-06 | Chugai Seiyaku Kabushiki Kaisha | ANTI-C5 ANTIBODIES AND THEIR METHODS OF USE |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US11365265B2 (en) | 2017-12-13 | 2022-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
RU2786053C2 (ru) * | 2017-01-31 | 2022-12-16 | Чугаи Сейяку Кабусики Кайся | Фармацевтическая композиция для применения для лечения или предупреждения с5-связанного заболевания и способ лечения или предупреждения с5-связанного заболевания |
US11780912B2 (en) | 2016-08-05 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of IL-8 related diseases |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
US10280215B2 (en) * | 2013-01-31 | 2019-05-07 | Seoul National University R&Db Foundation | Anti-C5 antibodies and methods of treating complement-related diseases |
SI3280440T1 (sl) | 2015-04-06 | 2023-03-31 | Bioverativ Usa Inc. | Humanizirana protitelesa proti C1S in načini uporabe |
JP7328479B2 (ja) * | 2016-03-23 | 2023-08-17 | ソウル大学校産学協力団 | 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途 |
EP3464351A1 (en) * | 2016-06-07 | 2019-04-10 | Novartis AG | Anti-c5 antibody for treating patients with complement c5 polymorphism |
MX2019004259A (es) * | 2016-10-12 | 2019-09-27 | Bioverativ Usa Inc | Anticuerpos anti-c1s y metodos de uso de los mismos. |
US11578137B2 (en) * | 2017-03-06 | 2023-02-14 | The Trustees Of The University Of Pennsylvania | Anti-C5 antibodies and uses thereof |
JP6672516B2 (ja) * | 2018-08-01 | 2020-03-25 | 中外製薬株式会社 | C5関連疾患の治療または予防用の医薬組成物およびc5関連疾患を治療または予防するための方法 |
CN111234016B (zh) * | 2020-02-23 | 2021-09-07 | 北京康普美特创新医药科技有限责任公司 | 一种抗补体c5分子的全人源单克隆抗体及应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355245B1 (en) * | 1994-05-02 | 2002-03-12 | Alexion Pharmaceuticals, Inc. | C5-specific antibodies for the treatment of inflammatory diseases |
US6518402B1 (en) * | 1994-08-23 | 2003-02-11 | Millennium Pharmaceuticals, Inc. | Antibodies to c5 polypeptides |
US6534058B2 (en) * | 2000-10-10 | 2003-03-18 | Tanox, Inc. | Anti-C5 monoclonal antibodies |
KR20100015773A (ko) * | 2007-03-22 | 2010-02-12 | 노파르티스 아게 | C5 항원 및 그의 용도 |
US7700740B2 (en) * | 2001-11-21 | 2010-04-20 | Celltech R&D Ltd | Antibodies to CD83 |
KR20110038173A (ko) * | 2008-08-05 | 2011-04-13 | 노파르티스 아게 | 보체 단백질 c5를 표적으로 하는 항체의 조성물 및 방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0619657A2 (pt) * | 2005-11-04 | 2011-11-08 | Genentech Inc | métodos de prevenção ou melhoria de doença ocular, uso de um inibidor de complemento, uso de um sirna especìfico para uma proteìna do sistema complemento e uso de um ácido nucleico que codifica um inibidor do sistema complemento |
EP2596807B1 (en) * | 2006-03-08 | 2015-12-16 | Archemix LLC | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
US7776573B2 (en) * | 2006-06-01 | 2010-08-17 | Genentech, Inc. | Crystal structure of CRIg and C3b:CRIg complex |
EP2164873B2 (en) | 2007-05-31 | 2018-09-12 | Genmab A/S | Stable igg4 antibodies |
US8442776B2 (en) * | 2007-06-08 | 2013-05-14 | The Trustees Of The University Of Pennsylvania | Structure of compstatin-C3 complex and use for rational drug design |
NZ606825A (en) * | 2008-11-10 | 2014-10-31 | Alexion Pharma Inc | Methods and compositions for treating complement-associated disorders |
ES2615732T3 (es) * | 2010-03-01 | 2017-06-08 | Alexion Pharmaceuticals, Inc. | Composiciones para tratar la enfermedad de Degos |
TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
CA2899433A1 (en) * | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
US10280215B2 (en) * | 2013-01-31 | 2019-05-07 | Seoul National University R&Db Foundation | Anti-C5 antibodies and methods of treating complement-related diseases |
-
2014
- 2014-02-03 US US14/764,885 patent/US10280215B2/en active Active
- 2014-02-03 RU RU2015136078A patent/RU2663349C2/ru active
- 2014-02-03 BR BR112015018438A patent/BR112015018438A2/pt not_active Application Discontinuation
- 2014-02-03 JP JP2015555921A patent/JP6608702B2/ja active Active
- 2014-02-03 EP EP14746443.2A patent/EP2975055A4/en active Pending
- 2014-02-03 CA CA2899589A patent/CA2899589C/en active Active
- 2014-02-03 RU RU2018125515A patent/RU2018125515A/ru not_active Application Discontinuation
- 2014-02-03 WO PCT/KR2014/000920 patent/WO2014119969A1/ko active Application Filing
- 2014-02-03 KR KR1020140012235A patent/KR101638931B1/ko active IP Right Grant
- 2014-02-03 CN CN201480019466.4A patent/CN105143261B/zh active Active
- 2014-02-03 AU AU2014213147A patent/AU2014213147B2/en active Active
-
2019
- 2019-04-15 AU AU2019202606A patent/AU2019202606B2/en active Active
- 2019-04-18 US US16/388,550 patent/US11339210B2/en active Active
- 2019-10-24 JP JP2019193551A patent/JP7019198B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355245B1 (en) * | 1994-05-02 | 2002-03-12 | Alexion Pharmaceuticals, Inc. | C5-specific antibodies for the treatment of inflammatory diseases |
US6518402B1 (en) * | 1994-08-23 | 2003-02-11 | Millennium Pharmaceuticals, Inc. | Antibodies to c5 polypeptides |
US6534058B2 (en) * | 2000-10-10 | 2003-03-18 | Tanox, Inc. | Anti-C5 monoclonal antibodies |
US7700740B2 (en) * | 2001-11-21 | 2010-04-20 | Celltech R&D Ltd | Antibodies to CD83 |
KR20100015773A (ko) * | 2007-03-22 | 2010-02-12 | 노파르티스 아게 | C5 항원 및 그의 용도 |
KR20110038173A (ko) * | 2008-08-05 | 2011-04-13 | 노파르티스 아게 | 보체 단백질 c5를 표적으로 하는 항체의 조성물 및 방법 |
Non-Patent Citations (4)
Title |
---|
"Remington: The Science and Practice of Pharmacy", 2000, MACK PUBLISHING CO. |
"Sustained and Controlled Release Drug Delivery Systems", 1978, MARCEL DEKKER, INC. |
KIM HYO LEE: "Antibody against MG 4 domain of human complement C5 potently inhibits C5 cleavage and activation", DOCTORAL THESIS, 31 August 2013 (2013-08-31), pages 1 - 80, XP009508661 * |
See also references of EP2975055A4 |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US10472623B2 (en) | 2008-04-11 | 2019-11-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US11359194B2 (en) | 2008-04-11 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US9890377B2 (en) | 2008-04-11 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US11371039B2 (en) | 2008-04-11 | 2022-06-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
US10023630B2 (en) | 2014-12-19 | 2018-07-17 | Chugai Seiyaku Kabushiki Kaisha | Methods of neutralizing C5 with anti-C5 antibodies |
US10385122B2 (en) | 2014-12-19 | 2019-08-20 | Chugai Seiyaku Kabushiki Kaisha | Nucleic acids encoding anti-C5 antibodies |
US11597760B2 (en) | 2014-12-19 | 2023-03-07 | Chugai Seiyaku Kabushiki Kaisha | Method of detecting the presence of complement C5 |
US9765135B2 (en) | 2014-12-19 | 2017-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies |
KR20180029267A (ko) * | 2014-12-19 | 2018-03-20 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 그의 사용 방법 |
KR102515796B1 (ko) * | 2014-12-19 | 2023-03-30 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 그의 사용 방법 |
JP2017200489A (ja) * | 2014-12-19 | 2017-11-09 | 中外製薬株式会社 | 抗c5抗体および使用方法 |
EP3390442A4 (en) * | 2015-12-18 | 2021-01-06 | Chugai Seiyaku Kabushiki Kaisha | ANTI-C5 ANTIBODIES AND THEIR METHODS OF USE |
TWI812979B (zh) * | 2015-12-18 | 2023-08-21 | 日商中外製藥股份有限公司 | 抗c5抗體及使用方法 |
US11479602B2 (en) | 2016-06-14 | 2022-10-25 | Regeneren Pharmaceuticals, Inc. | Methods of treating C5-associated diseases comprising administering anti-C5 antibodies |
US11492392B2 (en) | 2016-06-14 | 2022-11-08 | Regeneran Pharmaceuticals, Inc. | Polynucleotides encoding anti-C5 antibodies |
US10633434B2 (en) | 2016-06-14 | 2020-04-28 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibodies |
JP2017226655A (ja) * | 2016-06-17 | 2017-12-28 | 中外製薬株式会社 | 抗c5抗体および使用方法 |
JP6202774B1 (ja) * | 2016-06-17 | 2017-09-27 | 中外製薬株式会社 | 抗c5抗体および使用方法 |
US11780912B2 (en) | 2016-08-05 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of IL-8 related diseases |
RU2786053C2 (ru) * | 2017-01-31 | 2022-12-16 | Чугаи Сейяку Кабусики Кайся | Фармацевтическая композиция для применения для лечения или предупреждения с5-связанного заболевания и способ лечения или предупреждения с5-связанного заболевания |
US11365265B2 (en) | 2017-12-13 | 2022-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2014213147B2 (en) | 2019-01-17 |
AU2014213147A1 (en) | 2015-08-20 |
RU2018125515A (ru) | 2018-10-29 |
US20160068592A1 (en) | 2016-03-10 |
US11339210B2 (en) | 2022-05-24 |
US20190382472A1 (en) | 2019-12-19 |
CA2899589C (en) | 2022-02-22 |
EP2975055A4 (en) | 2016-11-02 |
AU2019202606B2 (en) | 2021-04-15 |
KR101638931B1 (ko) | 2016-07-12 |
CN105143261A (zh) | 2015-12-09 |
RU2015136078A (ru) | 2017-03-07 |
JP2020031650A (ja) | 2020-03-05 |
JP2016513088A (ja) | 2016-05-12 |
AU2019202606A1 (en) | 2019-05-02 |
CA2899589A1 (en) | 2014-08-07 |
JP7019198B2 (ja) | 2022-02-15 |
JP6608702B2 (ja) | 2019-11-20 |
BR112015018438A2 (pt) | 2017-07-18 |
EP2975055A1 (en) | 2016-01-20 |
RU2018125515A3 (ko) | 2021-11-19 |
US10280215B2 (en) | 2019-05-07 |
CN105143261B (zh) | 2021-04-09 |
RU2663349C2 (ru) | 2018-08-03 |
KR20150035354A (ko) | 2015-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014119969A1 (ko) | 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법 | |
JP6723293B2 (ja) | 黄色ブドウ球菌(Staphylococcus aureus)α毒素に特異的に結合する抗体及び使用方法 | |
US7521051B2 (en) | Methods of upmodulating adaptive immune response using anti-PD-1 antibodies | |
TW201704259A (zh) | 新穎之il33型式、il33之突變型式、抗體、試驗及其使用方法 | |
AU2012214531A1 (en) | Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use | |
WO2017074013A1 (ko) | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 | |
JP2022541192A (ja) | 抗pd-l1抗体 | |
WO2022216014A1 (ko) | 항-cntn4 항체 및 그의 용도 | |
WO2023234748A1 (ko) | 항-tigit 항체 및 이의 용도 | |
KR20240007256A (ko) | 이황화 결합된 결합 폴리펩타이드의 스크리닝 및 발현 방법 | |
JP2023543493A (ja) | ヒトクローディン18.2を標的とする抗体及びその使用 | |
KR20210158693A (ko) | 항 pcsk9 항체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480019466.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14746443 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2899589 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14764885 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015555921 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015018438 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2014213147 Country of ref document: AU Date of ref document: 20140203 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014746443 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015136078 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112015018438 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150731 |